Synthetic lethality and context-selective DNA-damage response dependencies: from genetic vulnerability to pharmacological translation
Open Access
- 11 September 2026
- journal article
- Published by Elsevier in Drug Discovery Today
- Vol. 31 (6)
Abstract
No abstract availableFunding Information
- Ministry of Food and Drug Safety (RS-2026-25521357)
- Ministry of Education (2021R1A6C101A442)
- National Research Foundation of Korea
- Korea Basic Science Institute
- Ministry of Science and ICT, South Korea (RS-2024-00401816)
- Ministry of Science and ICT, South Korea (RS-2025-21322968)
This publication has 63 references indexed in Scilit:
- PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancersCancer Letters, 2020
- Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expressionBreast Cancer Research and Treatment, 2019
- Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibitionCancer Treatment Reviews, 2018
- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic LethalityCancer Cell, 2018
- Defining a Cancer Dependency MapCell, 2017
- Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolaseDNA Repair, 2017
- Endogenous DNA Damage as a Source of Genomic Instability in CancerCell, 2017
- High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer LiabilitiesCell, 2015
- The DNA Damage Response: Making It Safe to Play with KnivesMolecular Cell, 2010
- The Deubiquitinating Enzyme USP1 Regulates the Fanconi Anemia PathwayMolecular Cell, 2005